GREACE STUDY PDF

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Read article at publisher's site DOI : Curr Med Res Opin.

Author:Kizuru Mazulkree
Country:Grenada
Language:English (Spanish)
Genre:Life
Published (Last):16 October 2014
Pages:201
PDF File Size:16.54 Mb
ePub File Size:9.63 Mb
ISBN:392-9-80146-506-5
Downloads:64365
Price:Free* [*Free Regsitration Required]
Uploader:Vigar



Background: Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. The primary outcome of our post-hoc analysis was risk reduction for first recurrent cardiovascular event in patients treated with a statin who had moderately abnormal liver tests defined as serum alanine aminotransferase or aspartate aminotransferase concentrations of less than three times the upper limit of normal compared with patients with abnormal liver tests who did not receive a statin.

This risk reduction was compared with that for patients treated or not with statin and normal liver tests. Interpretation: Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel.

Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.

Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results. Optional text in email:.

Save Cancel. Create a file for external citation management software Create file Cancel. Full-text links Cite Favorites. Abstract Background: Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. Funding: None. Comment in Liver tests are irrelevant when prescribing statins.

Bader T. Epub Nov PMID: No abstract available. Mearns BM. Nat Rev Cardiol. Raised liver enzymes in patients taking statins.

PURLs: statins for patients with nonalcoholic fatty liver? Egan M, Prasad S. Egan M, et al. J Fam Pract. Similar articles Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Tikkanen MJ, et al. Int J Cardiol.

Epub Aug Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC, et al.

N Engl J Med. Epub Mar 8. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation GREACE Study. Athyros VG, et al. Nephrol Dial Transplant. Epub Sep PMID: Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, et al. J Manag Care Pharm. PMID: Review. Curr Vasc Pharmacol. Show more similar articles See all similar articles. Sandhu N, Navarro V. Sandhu N, et al. Hepatol Commun. Francis P, Forman L. Francis P, et al. Clin Liver Dis Hoboken. No abstract available. Wang W, et al. Diabetes Metab J. Epub Dec 3. Klaebel JH, et al.

Li J, et al. Show more "Cited by" articles See all "Cited by" articles. Publication types Randomized Controlled Trial Actions. Research Support, Non-U. Gov't Actions. MeSH terms Aged Actions. Female Actions. Greece Actions. Humans Actions. Liver Function Tests Actions. Male Actions.

Middle Aged Actions. Non-alcoholic Fatty Liver Disease Actions. Prospective Studies Actions. Recurrence Actions. Risk Reduction Behavior Actions. Time Factors Actions. Treatment Outcome Actions. Full-text links [x] Elsevier Science. Copy Download.

CIRCUITOS DE CORRIENTE ALTERNA KERCHNER CORCORAN PDF

The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Published in The Lancet in Background Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. The primary outcome of our post-hoc analysis was risk reduction for first recurrent cardiovascular event in patients treated with a statin who had moderately abnormal liver tests defined as serum alanine aminotransferase or aspartate aminotransferase concentrations of less than three times the upper limit of normal compared with patients with abnormal liver tests who did not receive a statin. This risk reduction was compared with that for patients treated or not with statin and normal liver tests. Interpretation Stalin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease. Athyros, Vasilios G.

1N4735A DATASHEET PDF

GREACE (GREek Atorvastatin Coronary-heart-disease Evaluation) study

Background: Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol LDL-C levels. However, there is no long-term survival study that evaluated this statin. Patients-methods: To assess the effect of atorvastatin on morbidity and mortality total and coronary of patients with established coronary heart disease CHD , consecutive patients were randomised either to atorvastatin or to 'usual' medical care. All patients were followed up for a mean period of 3 years. Main outcome measures: Primary endpoints of the study were defined as death, non-fatal myocardial infarction, unstable angina, congestive heart failure, revascularisation coronary morbidity and stroke.

DRIFTWORKS LYOTARD PDF

.

KARL MARX HET KAPITAAL PDF

.

Related Articles